Secondary efficacy endpoints by body weight and dose group following adalimumab administration in pediatric patients with CD
| Body Weight/Dose | Clinical Response at Week 26 | Clinical Remission at Week 52 | Clinical Response at Week 52 |
|---|---|---|---|
| <40 kg (N = 60) | |||
| 10 mg (N = 31) | 13/31 (41.9%) | 5/31 (16.1%) | 8/31 (25.8%) |
| 20 mg (N = 29) | 14/29 (48.3%) | 8/29 (27.6%) | 11/29 (37.9%) |
| ≥40 kg (N = 128) | |||
| 20 mg (N = 64) | 33/64 (51.6%) | 17/64 (26.6%) | 19/64 (29.7%) |
| 40 mg (N = 64) | 41/64 (64.1%) | 23/64 (35.9%) | 28/64 (43.8%) |